
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
Daniele Focosi, Marco Tuccori, Andreina Baj, et al.
Viruses (2021) Vol. 13, Iss. 7, pp. 1211-1211
Open Access | Times Cited: 38
Daniele Focosi, Marco Tuccori, Andreina Baj, et al.
Viruses (2021) Vol. 13, Iss. 7, pp. 1211-1211
Open Access | Times Cited: 38
Showing 1-25 of 38 citing articles:
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 971
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 971
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 118
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 118
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89
Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies
Maryam Noori, Seyed Aria Nejadghaderi, Shahnam Arshi, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 73
Maryam Noori, Seyed Aria Nejadghaderi, Shahnam Arshi, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 73
SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines
Abbas Khan, Taimoor Ashraf Khan, Shughla Ali, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112176-112176
Open Access | Times Cited: 71
Abbas Khan, Taimoor Ashraf Khan, Shughla Ali, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112176-112176
Open Access | Times Cited: 71
SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
Elizabeth‐Barbara Tatsi, Filippos Filippatos, Athanasios Michos
Epidemiology and Infection (2021) Vol. 149
Open Access | Times Cited: 54
Elizabeth‐Barbara Tatsi, Filippos Filippatos, Athanasios Michos
Epidemiology and Infection (2021) Vol. 149
Open Access | Times Cited: 54
COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
Domenico Iacopetta, Jessica Ceramella, Alessia Catalano, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 573-573
Open Access | Times Cited: 49
Domenico Iacopetta, Jessica Ceramella, Alessia Catalano, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 573-573
Open Access | Times Cited: 49
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
Kyle P. Martin, Christine Grimaldi, Rolf Grempler, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 36
Kyle P. Martin, Christine Grimaldi, Rolf Grempler, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 36
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
Mohammad Reza Zinatizadeh, Peyman Kheirandish Zarandi, Maryam Zinatizadeh, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112527-112527
Open Access | Times Cited: 42
Mohammad Reza Zinatizadeh, Peyman Kheirandish Zarandi, Maryam Zinatizadeh, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112527-112527
Open Access | Times Cited: 42
COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme
Clare L. Fasching, Venice Servellita, Bridget McKay, et al.
Journal of Clinical Microbiology (2022) Vol. 60, Iss. 7
Open Access | Times Cited: 28
Clare L. Fasching, Venice Servellita, Bridget McKay, et al.
Journal of Clinical Microbiology (2022) Vol. 60, Iss. 7
Open Access | Times Cited: 28
COVID-19 in Latin America: A Snapshot in Time and the Road Ahead
J LaRotta, Omar Escobar, María L. Ávila-Agüero, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 389-410
Open Access | Times Cited: 18
J LaRotta, Omar Escobar, María L. Ávila-Agüero, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 389-410
Open Access | Times Cited: 18
Blockchain-Based Trusted Tracking Smart Sensing Network to Prevent the Spread of Infectious Diseases
Riaz Ullah Khan, Rajesh Kumar, Amin Ul Haq, et al.
IRBM (2024) Vol. 45, Iss. 2, pp. 100829-100829
Closed Access | Times Cited: 5
Riaz Ullah Khan, Rajesh Kumar, Amin Ul Haq, et al.
IRBM (2024) Vol. 45, Iss. 2, pp. 100829-100829
Closed Access | Times Cited: 5
Molecular detection of SARS‐CoV‐2 strains and differentiation of Delta variant strains
Vaughn Hamill, Lance Noll, Nanyan Lu, et al.
Transboundary and Emerging Diseases (2021) Vol. 69, Iss. 5, pp. 2879-2889
Open Access | Times Cited: 31
Vaughn Hamill, Lance Noll, Nanyan Lu, et al.
Transboundary and Emerging Diseases (2021) Vol. 69, Iss. 5, pp. 2879-2889
Open Access | Times Cited: 31
Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity
Fuhua Wu, Shuang Luo, Yongshun Zhang, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 5, pp. 2219-2233
Open Access | Times Cited: 20
Fuhua Wu, Shuang Luo, Yongshun Zhang, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 5, pp. 2219-2233
Open Access | Times Cited: 20
SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy
Desh Deepak Singh, Anshul Sharma, Hae‐Jeung Lee, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 19
Desh Deepak Singh, Anshul Sharma, Hae‐Jeung Lee, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 19
Probabilistic Approach to COVID-19 Data Analysis and Forecasting Future Outbreaks Using a Multi-Layer Perceptron Neural Network
Riaz Ullah Khan, Sultan Almakdi, Mohammed S. Alshehri, et al.
Diagnostics (2022) Vol. 12, Iss. 10, pp. 2539-2539
Open Access | Times Cited: 18
Riaz Ullah Khan, Sultan Almakdi, Mohammed S. Alshehri, et al.
Diagnostics (2022) Vol. 12, Iss. 10, pp. 2539-2539
Open Access | Times Cited: 18
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future
Marco Tuccori, Irma Convertino, Sara Ferraro, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 12, pp. 1403-1414
Open Access | Times Cited: 24
Marco Tuccori, Irma Convertino, Sara Ferraro, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 12, pp. 1403-1414
Open Access | Times Cited: 24
Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
Rafael Bayarri‐Olmos, Ida Jarlhelt, Laust Bruun Johnsen, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 24
Rafael Bayarri‐Olmos, Ida Jarlhelt, Laust Bruun Johnsen, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 24
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
Sandrine M. Soh, Yeong-Jun Kim, Chanwoo Kim, et al.
The Journal of Microbiology (2021) Vol. 59, Iss. 9, pp. 807-818
Open Access | Times Cited: 21
Sandrine M. Soh, Yeong-Jun Kim, Chanwoo Kim, et al.
The Journal of Microbiology (2021) Vol. 59, Iss. 9, pp. 807-818
Open Access | Times Cited: 21
High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!
Susy Fanny Núñez-Zapata, Bruno Benites-Peralta, Percy Mayta‐Tristán, et al.
International Journal of Infectious Diseases (2021) Vol. 109, pp. 244-246
Open Access | Times Cited: 20
Susy Fanny Núñez-Zapata, Bruno Benites-Peralta, Percy Mayta‐Tristán, et al.
International Journal of Infectious Diseases (2021) Vol. 109, pp. 244-246
Open Access | Times Cited: 20
Comparative mutational analysis of SARS-CoV-2 isolates from Pakistan and structural-functional implications using computational modelling and simulation approaches
Abdullah Shah, Saira Rehmat, Iqra Aslam, et al.
Computers in Biology and Medicine (2021) Vol. 141, pp. 105170-105170
Open Access | Times Cited: 20
Abdullah Shah, Saira Rehmat, Iqra Aslam, et al.
Computers in Biology and Medicine (2021) Vol. 141, pp. 105170-105170
Open Access | Times Cited: 20
The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy
Sawsan S. Alamri, Ahdab Alsaieedi, Yousef Khouqeer, et al.
PeerJ (2023) Vol. 11, pp. e15024-e15024
Open Access | Times Cited: 8
Sawsan S. Alamri, Ahdab Alsaieedi, Yousef Khouqeer, et al.
PeerJ (2023) Vol. 11, pp. e15024-e15024
Open Access | Times Cited: 8
Are convalescent plasma stocks collected during former COVID‐19 waves still effective against current SARS‐CoV ‐2 variants?
Daniele Focosi, Massimo Franchini, Michael J. Joyner, et al.
Vox Sanguinis (2022) Vol. 117, Iss. 5, pp. 641-646
Closed Access | Times Cited: 12
Daniele Focosi, Massimo Franchini, Michael J. Joyner, et al.
Vox Sanguinis (2022) Vol. 117, Iss. 5, pp. 641-646
Closed Access | Times Cited: 12
Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile
Jeffrey M. Sturek, Tania A. Thomas, James D. Gorham, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Jeffrey M. Sturek, Tania A. Thomas, James D. Gorham, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents
Jacek Plichta, Piotr Kuna, Michał Panek
COVID (2022) Vol. 2, Iss. 5, pp. 599-620
Open Access | Times Cited: 9
Jacek Plichta, Piotr Kuna, Michał Panek
COVID (2022) Vol. 2, Iss. 5, pp. 599-620
Open Access | Times Cited: 9